Abstract
A 36-year-old female nurse developed a persistent erythematous rash following accidental exposure of uncovered skin to iloprost. To our knowledge, this is the first report of occupational contact erythema to Iloprost, a stable analogue of prostacycline that is being used as a vasodilating agent in therapeutic clinical trials. Topical application of iloprost causes persistent erythema as a direct pharmacological effect due to percutaneous absorption. This article discusses the possible relationship between this effect and the pathophysiology of so called nonimmunologic contact urticaria.
Get full access to this article
View all access options for this article.